Stig Linder

8.9k total citations
151 papers, 7.1k citations indexed

About

Stig Linder is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Stig Linder has authored 151 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Molecular Biology, 51 papers in Oncology and 31 papers in Cell Biology. Recurrent topics in Stig Linder's work include Ubiquitin and proteasome pathways (42 papers), Cell death mechanisms and regulation (24 papers) and Cancer-related Molecular Pathways (21 papers). Stig Linder is often cited by papers focused on Ubiquitin and proteasome pathways (42 papers), Cell death mechanisms and regulation (24 papers) and Cancer-related Molecular Pathways (21 papers). Stig Linder collaborates with scholars based in Sweden, United States and Germany. Stig Linder's co-authors include Maria C. Shoshan, Pádraig D’Arcy, Maria Hägg Olofsson, Aleksandra Mandic, Johan Hansson, Xiaonan Zhang, Rolf Larsson, Mårten Fryknäs, Aleksandra Mandic Havelka and Takayuki Ueno and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Stig Linder

149 papers receiving 7.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Stig Linder 4.8k 2.0k 1.0k 1.0k 981 151 7.1k
Jennifer S. Carew 4.8k 1.0× 1.4k 0.7× 661 0.6× 1.4k 1.3× 1.4k 1.5× 95 6.7k
Gabriella D’Orazi 3.8k 0.8× 2.3k 1.2× 540 0.5× 917 0.9× 1.5k 1.5× 131 6.3k
Frank A.E. Kruyt 5.7k 1.2× 2.3k 1.2× 757 0.7× 739 0.7× 1.7k 1.7× 140 7.9k
Henning R. Stennicke 6.6k 1.4× 1.5k 0.7× 909 0.9× 933 0.9× 938 1.0× 56 8.9k
Alexandru Almasan 4.4k 0.9× 1.9k 0.9× 469 0.5× 671 0.7× 1.0k 1.0× 96 6.5k
Yinkun Liu 3.4k 0.7× 1.3k 0.7× 714 0.7× 584 0.6× 1.3k 1.4× 200 5.5k
Lisa Bouchier‐Hayes 5.3k 1.1× 1.8k 0.9× 595 0.6× 1.0k 1.0× 885 0.9× 52 7.2k
Edward V. Prochownik 6.4k 1.3× 2.1k 1.0× 804 0.8× 461 0.5× 1.8k 1.8× 170 8.6k
Damu Tang 3.8k 0.8× 1.5k 0.7× 753 0.7× 492 0.5× 1.3k 1.3× 132 6.0k
Jun Zhou 4.8k 1.0× 1.7k 0.9× 1.9k 1.9× 528 0.5× 726 0.7× 190 6.8k

Countries citing papers authored by Stig Linder

Since Specialization
Citations

This map shows the geographic impact of Stig Linder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stig Linder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stig Linder more than expected).

Fields of papers citing papers by Stig Linder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stig Linder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stig Linder. The network helps show where Stig Linder may publish in the future.

Co-authorship network of co-authors of Stig Linder

This figure shows the co-authorship network connecting the top 25 collaborators of Stig Linder. A scholar is included among the top collaborators of Stig Linder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stig Linder. Stig Linder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ecke, Thorsten, Johan Styrke, Kiran Jagarlamudi, & Stig Linder. (2025). Development of point-of-care tests for urinary bladder cancer – an historic review and view to future prospectives. Urologic Oncology Seminars and Original Investigations. 43(7). 401–411. 1 indexed citations
2.
Murtola, Teemu J., Aino Siltari, Teuvo L.J. Tammela, et al.. (2024). Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer. European Urology Open Science. 70. 135–141. 2 indexed citations
3.
4.
Pellegrini, Paola, et al.. (2020). Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570. International Journal of Molecular Sciences. 21(13). 4757–4757. 13 indexed citations
5.
Bazzaro, Martina & Stig Linder. (2020). Dienone Compounds: Targets and Pharmacological Responses. Journal of Medicinal Chemistry. 63(24). 15075–15093. 12 indexed citations
6.
Zhang, Xiaonan, Karthik Selvaraju, Amir Ata Saei, et al.. (2019). Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug. Biochimie. 162. 46–54. 131 indexed citations
7.
Mullany, Sally A., et al.. (2019). Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer. International Journal of Molecular Sciences. 20(1). 229–229. 87 indexed citations
8.
Zhang, Xiaonan, Belén Espinosa, Amir Ata Saei, et al.. (2019). Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment. Oxidative Medicine and Cellular Longevity. 2019. 1–11. 13 indexed citations
9.
10.
11.
Stafford, William C., Xiaoxiao Peng, Maria Hägg Olofsson, et al.. (2018). Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Science Translational Medicine. 10(428). 164 indexed citations
12.
Wang, Xin, Magdalena Mazurkiewicz, Ellin‐Kristina Hillert, et al.. (2016). The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Scientific Reports. 6(1). 26979–26979. 133 indexed citations
13.
Senkowski, Wojciech, Xiaonan Zhang, Maria Hägg Olofsson, et al.. (2015). Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer. Molecular Cancer Therapeutics. 14(6). 1504–1516. 118 indexed citations
14.
Thulin, Petra, Gunnar Nordahl, Marcus Gry, et al.. (2013). Keratin‐18 and micro RNA ‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts. Liver International. 34(3). 367–378. 89 indexed citations
15.
Brnjic, Slavica, Magdalena Mazurkiewicz, Mårten Fryknäs, et al.. (2013). Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress. Antioxidants and Redox Signaling. 21(17). 2271–2285. 66 indexed citations
16.
Fryknäs, Mårten, Joachim Gullbo, Xin Wang, et al.. (2013). Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance. BMC Cancer. 13(1). 374–374. 8 indexed citations
17.
Marino, Maria Lucia, Paola Pellegrini, Giuseppe Di Lernia, et al.. (2012). Autophagy Is a Protective Mechanism for Human Melanoma Cells under Acidic Stress. Journal of Biological Chemistry. 287(36). 30664–30676. 144 indexed citations
18.
Brnjic, Slavica, Maria Hägg Olofsson, Aleksandra Mandic Havelka, & Stig Linder. (2010). Chemical biology suggests a role for calcium signaling in mediating sustained JNKactivation during apoptosis. Molecular BioSystems. 6(5). 767–774. 34 indexed citations
19.
Viktorsson, Kristina, et al.. (2000). Increased apoptosis and increased clonogenic survival of 12V-H-ras transformed rat fibroblasts in response to cisplatin. APOPTOSIS. 5(4). 355–367. 8 indexed citations
20.
Engel, Georg, et al.. (1993). Repression of stromelysin metalloprotease expression in rat fibrosarcoma cells by dimethylsulfoxide. Clinical & Experimental Metastasis. 11(1). 77–82. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer S. Carew Breakdown of academic impact, for papers by Gabriella D’Orazi Breakdown of academic impact, for papers by Frank A.E. Kruyt Breakdown of academic impact, for papers by Henning R. Stennicke Breakdown of academic impact, for papers by Alexandru Almasan Breakdown of academic impact, for papers by Yinkun Liu Breakdown of academic impact, for papers by Lisa Bouchier‐Hayes Breakdown of academic impact, for papers by Edward V. Prochownik Breakdown of academic impact, for papers by Damu Tang Breakdown of academic impact, for papers by Jun Zhou
Rankless by CCL
2026